IL325232A - Pi3k inhibitors and use thereof - Google Patents
Pi3k inhibitors and use thereofInfo
- Publication number
- IL325232A IL325232A IL325232A IL32523225A IL325232A IL 325232 A IL325232 A IL 325232A IL 325232 A IL325232 A IL 325232A IL 32523225 A IL32523225 A IL 32523225A IL 325232 A IL325232 A IL 325232A
- Authority
- IL
- Israel
- Prior art keywords
- pi3k inhibitors
- pi3k
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023101669 | 2023-06-21 | ||
| PCT/CN2024/100794 WO2024260464A1 (en) | 2023-06-21 | 2024-06-21 | Pi3k inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325232A true IL325232A (en) | 2026-02-01 |
Family
ID=87473801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325232A IL325232A (en) | 2023-06-21 | 2025-12-09 | Pi3k inhibitors and use thereof |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN121358736A (en) |
| AU (1) | AU2024314618A1 (en) |
| IL (1) | IL325232A (en) |
| WO (1) | WO2024260464A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121719A1 (en) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | ALLESTERIC INHIBITORS OF CHROMENONE OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES |
| KR20240014065A (en) * | 2021-05-27 | 2024-01-31 | 페트라 파마 코포레이션 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of cancer |
| WO2023081209A1 (en) * | 2021-11-03 | 2023-05-11 | Zeno Management, Inc. | Pi3k inhibitors and methods of treating cancer |
| WO2023078401A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Biosciences, Ltd. | Compounds as protein kinase inhibitors |
| CN118742545A (en) * | 2021-12-08 | 2024-10-01 | 南京征祥医药有限公司 | Fused heterocyclic compounds as PI3Kα inhibitors |
| WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
-
2024
- 2024-06-21 AU AU2024314618A patent/AU2024314618A1/en active Pending
- 2024-06-21 WO PCT/CN2024/100794 patent/WO2024260464A1/en active Pending
- 2024-06-21 CN CN202480040645.XA patent/CN121358736A/en active Pending
-
2025
- 2025-12-09 IL IL325232A patent/IL325232A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024260464A1 (en) | 2024-12-26 |
| AU2024314618A1 (en) | 2026-01-08 |
| CN121358736A (en) | 2026-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL325232A (en) | Pi3k inhibitors and use thereof | |
| IL325094A (en) | Pi3k-α inhibitors and methods of use thereof | |
| SG11202107614PA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL312348A (en) | Inhibitors of hif-2alpha and methods of use thereof | |
| SG11202107615TA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL324876A (en) | Parp1 inhibitors and uses thereof | |
| SG11202112158YA (en) | Kcnt1 inhibitors and methods of use | |
| IL300107A (en) | Quinazolinone hsd17b13 inhibitors and uses thereof | |
| IL287973A (en) | Acss2 inhibitors and methods of use thereof | |
| EP4370124A4 (en) | PI3Ka INHIBITORS AND METHODS OF USE THEREOF | |
| IL313636A (en) | Compounds and use thereof as hdac6 inhibitors | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| CA3251244A1 (en) | Pi3k.alpha. inhibitors and methods of use thereof | |
| IL283899A (en) | Combinations of hdm2-p53 interaction inhibitors and bcl2 inhibitor and their use in the treatment of cancer | |
| IL299700B1 (en) | Kcnt1 inhibitors and methods of use | |
| PL4337673T3 (en) | Psd-95 inhibitors and uses thereof | |
| GB202214644D0 (en) | Sars-cov-2 mpro inhibitors and uses thereof | |
| IL310209A (en) | Rock2 inhibitors and uses thereof | |
| IL312466A (en) | Pi3k-alpha inhibitors and methods of making and using the same | |
| IL305789A (en) | Usp30 inhibitors and uses thereof | |
| EP4051669A4 (en) | Ssao inhibitors and use thereof | |
| IL319049A (en) | Tyk2 inhibitors and uses thereof | |
| GB202511417D0 (en) | Selective bet inhibitors and uses thereof | |
| CA3295342A1 (en) | Pi3k inhibitors and use thereof |